Therapy in Different CML Phases
| CML Phase . | Therapy . | No. Treated . |
|---|---|---|
| Early chronic (N = 82) | IFN-α alone IFN-α + hydroxyurea | 5 37 |
| IFN-α + low-dose ara C | 20 | |
| IFN-α + homoharringtonine | 10 | |
| IFN-α + other | 8 | |
| Others | 2 | |
| Late chronic (N = 11) | IFN-α alone IFN-α + low-dose ara C | 3 4 |
| IFN-α + hydroxyurea | 1 | |
| Others | 3 | |
| Accelerated (N = 12) | IFN-α + hydroxyurea IFN-α + low dose area C | 4 3 |
| IFN-α + homoharringtonine | 2 | |
| Others | 3 | |
| Blastic (N = 5) | Combination chemotherapy CI973 | 4 1 |
| CML Phase . | Therapy . | No. Treated . |
|---|---|---|
| Early chronic (N = 82) | IFN-α alone IFN-α + hydroxyurea | 5 37 |
| IFN-α + low-dose ara C | 20 | |
| IFN-α + homoharringtonine | 10 | |
| IFN-α + other | 8 | |
| Others | 2 | |
| Late chronic (N = 11) | IFN-α alone IFN-α + low-dose ara C | 3 4 |
| IFN-α + hydroxyurea | 1 | |
| Others | 3 | |
| Accelerated (N = 12) | IFN-α + hydroxyurea IFN-α + low dose area C | 4 3 |
| IFN-α + homoharringtonine | 2 | |
| Others | 3 | |
| Blastic (N = 5) | Combination chemotherapy CI973 | 4 1 |